跳至主要内容
临床试验/NCT03920813
NCT03920813Unknown4 期

Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic

Shandong University0 个研究点目标入组 500 人开始时间: 2015年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
500
主要终点
Red blood cells (RBC) concentration of 6-mercaptopurine (6-MP)

研究概览

简要总结

The present study was conducted to assess the population pharmacokinetics of 6-mercaptopurine (6-MP) in Pediatric Acute Lymphoblastic Leukemia (ALL) and genetic polymorphisms

详细描述

The investigators' purpose was to identify genetic factors and metabolite concentrations associated with both hematological toxicity in patients with ALL maintained on 6-MP in Chinese.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
1 Year 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Patients have been diagnosed with Acute Lymphoblastic Leukemia
  • Childhood patients who were undergoing chemotherapy or continuous follow-up after completion of chemotherapy
  • Patients received the phase of maintenance therapy that included oral 6-MP (>4 weeks) and completion of ≥ 6 months according to the CCLG (Chinese Children's Leukemia Group) protocol-ALL 2015

排除标准

  • Patients with high-risk ALL (presence of higher-risk features: MRD ≥ 1% at 46 day, or age < 6 month and white blood cell (WBC) count ≥ 300×109/L with translocations t(9;22) (q34;q11) [BCR-ABL], t(4;11) (q21;q23) [AF4/MLL], t(1;19) (q23;p13) [E2A-PBX1] or other MLL-rearrangements) were removed

研究组 & 干预措施

Antitumor drugs

Experimental

Mercaptopurine administered at standard dose for children with hematological neoplasms.

干预措施: Mercaptopurine (Drug)

结局指标

主要结局

Red blood cells (RBC) concentration of 6-mercaptopurine (6-MP)

时间窗: at second day after oral administration

To detect of RBC 6-MP metabolite concentrations and evaluate the association of metabolite concentrations and side effects

Genetic polymorphisms in Chinese patients with ALL

时间窗: at second day after oral administration

To detect the frequencies of genetic polymorphisms of Chinese patients receiving 6-MP for treatment of ALL

次要结局

未报告次要终点

研究者

发起方
Shandong University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Wei Zhao

Head of department of clinical pharmacy and pharmacology

Shandong University

相似试验

Determinants of Mercaptopurine Toxicity in... | 临床试验